Comparing OpGen (OPGN) & Genomic Health (GHDX)

OpGen (NASDAQ: OPGN) and Genomic Health (NASDAQ:GHDX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

How to Become a New Pot Stock Millionaire

90.0% of Genomic Health shares are held by institutional investors. 31.8% of OpGen shares are held by company insiders. Comparatively, 46.2% of Genomic Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

OpGen has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Genomic Health has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Valuation & Earnings

This table compares OpGen and Genomic Health’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OpGen $3.21 million 3.15 -$15.41 million ($9.78) -0.20
Genomic Health $340.75 million 3.42 -$3.85 million $0.01 3,302.00

Genomic Health has higher revenue and earnings than OpGen. OpGen is trading at a lower price-to-earnings ratio than Genomic Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares OpGen and Genomic Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OpGen -479.38% -1,719.89% -228.38%
Genomic Health -1.13% -0.83% -0.66%

Analyst Ratings

This is a breakdown of current recommendations for OpGen and Genomic Health, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OpGen 0 0 2 0 3.00
Genomic Health 2 5 1 0 1.88

OpGen presently has a consensus target price of $9.00, indicating a potential upside of 371.20%. Genomic Health has a consensus target price of $32.67, indicating a potential downside of 1.07%. Given OpGen’s stronger consensus rating and higher probable upside, analysts plainly believe OpGen is more favorable than Genomic Health.

Summary

Genomic Health beats OpGen on 10 of the 14 factors compared between the two stocks.

OpGen Company Profile

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.

Genomic Health Company Profile

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype DX AR-V7 Nucleus Detect test for men with metastatic castration-resistant prostate cancer. The company offers its products through a network of distributors. Genomic Health, Inc. has collaboration agreement with Epic Sciences, Inc.; license and development agreement with Biocartis N.V.; license agreement with Cleveland Diagnostics, Inc.; and a research collaboration agreement with Janssen Pharmaceuticals. The company was founded in 2000 and is based in Redwood City, California.

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply